Orchid Chemicals and Pharmaceuticals is trading lower by 4.4% at Rs 73.60 after reporting over seven-fold year-on-year (YoY) jump in its net loss at Rs 72.36 crore in the October-December quarter (Q3) due to lower operational income and higher interest cost. The pharmaceutical company had a loss of Rs 10.12 crore in a year ago quarter.
“The overall performance of the company continues to witness pressure due to the tight working capital levels and debt leverage," said K Raghavendra Rao, chairman and managing director, Orchid Chemicals & Pharmaceuticals.
The company’s total income from operations in Q3FY13 has declined by 33% to Rs 322 crore from Rs 471 crore during the same quarter of previous fiscal, while finance cost increased 45% to Rs 71 crore on YoY basis.
The stock opened at Rs 75 and hit a 52-week low of Rs 72.85 on NSE. A combined 237,579 shares have changed hands on the counter in early morning deals on NSE and BSE.
“The overall performance of the company continues to witness pressure due to the tight working capital levels and debt leverage," said K Raghavendra Rao, chairman and managing director, Orchid Chemicals & Pharmaceuticals.
The company’s total income from operations in Q3FY13 has declined by 33% to Rs 322 crore from Rs 471 crore during the same quarter of previous fiscal, while finance cost increased 45% to Rs 71 crore on YoY basis.
The stock opened at Rs 75 and hit a 52-week low of Rs 72.85 on NSE. A combined 237,579 shares have changed hands on the counter in early morning deals on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%